Arcturus director receives 15,000 stock options

Arcturus Therapeutics Holdings Inc. reported that director Jing L. Marantz received a grant of stock options covering 15,000 shares of common stock.

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. reported that director Jing L. Marantz received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.30 per share and expire on June 5, 2036.

According to the disclosure, these options represent Dr. Marantz’s 2026 annual grant for service on the Board of Directors. The shares underlying the option vest monthly over one year from the grant date, and following this award she holds stock options for 15,000 shares directly.

Insights

Equity Compensation Analyst

Routine annual option grant to an Arcturus director, not a market trade.

The filing shows Jing L. Marantz, a director of Arcturus Therapeutics Holdings Inc., receiving stock options for 15,000 shares at an exercise price of $7.30 per share, expiring on June 5, 2036. This is coded as a grant/award acquisition.

The footnote explains this is the 2026 annual grant for Board service, with monthly vesting over one year. Such awards are standard equity compensation rather than open-market buying or selling, so the informational signal for investors is limited and best viewed as a routine governance and incentive practice.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Marantz Jing L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

Key Figures

Option grant size: 15,000 shares Exercise price: $7.30 per share Expiration date: June 5, 2036 +1 more

4 metrics

Option grant size 15,000 shares Stock options granted to director Jing L. Marantz

Exercise price $7.30 per share Strike price of newly granted stock options

Expiration date June 5, 2036 Option term for 15,000-share grant

Post-grant option holdings 15,000 options Total derivative holdings following the reported grant

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, vest monthly over a one year period, Board of Directors

4 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest monthly over a one year period financial

"Shares underlying the option vest monthly over a one year period"

Board of Directors financial

"as a member of the Board of Directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jing L. Marantz receive in the latest Arcturus (ARCT) Form 4?

Jing L. Marantz received a grant of stock options for 15,000 Arcturus shares. The options were granted as part of her Board service compensation and give her the right to buy common stock at a fixed exercise price.

What is the exercise price and term of the new Arcturus (ARCT) stock options?

The newly granted Arcturus stock options have an exercise price of $7.30 per share and expire on June 5, 2036. This defines the cost to purchase shares and the period in which the options can be exercised.

How do the Arcturus (ARCT) options granted to Jing L. Marantz vest?

The options granted to Jing L. Marantz vest monthly over one year from the grant date. This gradual vesting schedule ties continued Board service to the right to exercise the options over the first year.

Is the Jing L. Marantz option grant in Arcturus (ARCT) a market purchase or sale?

No, this Form 4 reflects a compensation-related grant, not a market trade. The transaction is coded as a grant or award acquisition, meaning the options were awarded by the company rather than bought or sold on the open market.

How many Arcturus (ARCT) options does Jing L. Marantz hold after this grant?

After the reported grant, Jing L. Marantz holds stock options covering 15,000 shares of Arcturus common stock directly. This reflects her derivative position from this specific award as disclosed in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marantz Jing L.

(Last) (First) (Middle)

C/O ARCTURUS THERAPEUTICS HOLDINGS INC.

10285 SCIENCE CENTER DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$7.3	06/05/2026		A		15,000		(1)	06/05/2036	Common Stock	15,000	$0.00	15,000	D

Explanation of Responses:

1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

	/s/ Ilan Katz, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)